Onconova Therapeutics Q2 EPS $(0.20) Beats $(0.31) Estimate, Sales $57.00K Miss $70.00K Estimate
Portfolio Pulse from totan@benzinga.com
Onconova Therapeutics reported Q2 losses of $(0.20) per share, beating the analyst consensus estimate of $(0.31) by 35.48%. However, the company's quarterly sales of $57.00K missed the estimate of $70.00K by 18.57%.
August 10, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Onconova Therapeutics' Q2 earnings beat estimates but sales missed, which could have mixed effects on the stock.
Onconova Therapeutics reported better than expected earnings per share, which is generally positive for the stock. However, the company missed sales estimates, which is typically negative. The mixed results could lead to uncertainty and volatility in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100